Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Boehringer Ingelheim
Colorcon
Mallinckrodt
Merck

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,001,876

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,001,876 protect, and when does it expire?

Patent 6,001,876 protects LYRICA and is included in two NDAs.

Protection for LYRICA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-one patent family members in twenty-three countries.

Summary for Patent: 6,001,876
Title: Isobutylgaba and its derivatives for the treatment of pain
Abstract:The instant invention is a method of using certain analogs of glutamic acid and gamma-aminobutyric acid in pain therapy.
Inventor(s): Singh; Lakhbir (Cambridgeshire, GB)
Assignee: Warner-Lambert Company (Morris Plains, NJ)
Application Number:09/043,358
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,001,876
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,001,876

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pf Prism Cv LYRICA pregabalin CAPSULE;ORAL 021446-001 Dec 30, 2004 AB RX Yes No   Start Trial   Start Trial   Start Trial
Pf Prism Cv LYRICA pregabalin CAPSULE;ORAL 021446-002 Dec 30, 2004 AB RX Yes No   Start Trial   Start Trial   Start Trial
Pf Prism Cv LYRICA pregabalin CAPSULE;ORAL 021446-003 Dec 30, 2004 AB RX Yes No   Start Trial   Start Trial   Start Trial
Pf Prism Cv LYRICA pregabalin CAPSULE;ORAL 021446-004 Dec 30, 2004 AB RX Yes No   Start Trial   Start Trial   Start Trial
Pf Prism Cv LYRICA pregabalin CAPSULE;ORAL 021446-005 Dec 30, 2004 AB RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,001,876

PCT Information
PCT FiledJuly 16, 1997PCT Application Number:PCT/US97/12390
PCT Publication Date:January 29, 1998PCT Publication Number: WO98/03167

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Medtronic
McKinsey
Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.